Overview

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

Status:
Completed
Trial end date:
2011-05-02
Target enrollment:
Participant gender:
Summary
This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose escalation/de-escalation phase to investigate the minimal efficacious dose based on PD markers with an acceptable safety profile.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Ofatumumab
Rituximab